Pfizer to acquire Arena Pharma; Takeda’s ...

Advances in genetics research have sparked a surge in interest in gene therapy in dermatology in recent years. Dermatology treatment options have expanded beyond topical drugs to include oral medications, injectables, and light and laser therapy. Now, rather than simply treating symptoms, gene therapy in dermatolog...

What is Gene Therapy and Is the Skin Suitable for Gene Therapy? Since its first discovery, conceptualization in 1972, and successful application in 1990 by W. French Anderson, gene therapy has been a revolutionary game-changer in the field of biotechnology and healthcare. Now, its scope reaches beyond autoimmune...

Pfizer tightens DMD patient criteria after serious adverse events in phase 3 gene therapy trial Pfizer is tightening up the criteria for Duchenne muscular dystrophy patients to partake in phase 3 clinical trials of its experimental gene therapy after three severe events were cropping up in ongoing studies. Th...

Cancer is a leading cause of global death, accounting for nearly 10 million deaths in 2020.  However, over the past years, the treatment paradigm of Cancer has transformed with several therapies such as chemotherapies, radiation therapies and immunotherapies available to treat cancer. Even then, there exists a...

BlueRock Therapeutics secures FDA fast track for Parkinson’s disease cell therapy BlueRock, a Bayer subsidiary, is currently assessing the pluripotent stem cell-derived dopaminergic neuron therapy in a phase 1 study. This early-stage trial is set to enroll ten patients across the US and Canada, with its prima...

Arrowhead Halts its ARO-ENaC Phase 1/2 Clinical Trial  Arrowhead Pharmaceuticals recently notified about its voluntary decision to put a pause on its ongoing Phase 1/2 clinical study of ARO-ENaC for patients with cystic fibrosis (CF). The announcement came after a preliminary update from an ongoing chronic ...